{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:25:56Z","timestamp":1789053956694,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHLT Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhlto.2026.100533","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T07:18:03Z","timestamp":1772867883000},"page":"100533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hepatitis B, C, and E viruses in solid organ transplantation: donor and recipient perspectives"],"prefix":"10.1016","volume":"12","author":[{"given":"Jehanzaeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Kozuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-5629","authenticated-orcid":false,"given":"Saima","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhlto.2026.100533_bib1","unstructured":"WHO GLOBAL HEPATITIS REPORT 2024 [Internet]. 2024 [cited 2025 July 3]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/\u3008https:\/\/www.worldhepatitisalliance.org\/wp-content\/uploads\/2024\/07\/WHA-Global-Hepatitis-Report_FINAL.pdf\u3009."},{"issue":"9","key":"10.1016\/j.jhlto.2026.100533_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019407","article-title":"Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients","volume":"99","author":"\u00c1lvarez-L\u00d3pez","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.transproceed.2012.03.040","article-title":"Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation","volume":"44","author":"Chen","year":"2012","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70054","article-title":"Hepatitis B virus donor positive to recipient negative (D+\/R-) heart and lung transplantation: analysis from the Organ Procurement and Transplantation Network","volume":"27","author":"Belga","year":"2025","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib5","first-page":"55","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jhlto.2026.100533_bib6","unstructured":"DailyMed - VEMLIDY- tenofovir alafenamide tablet [Internet]. [cited 2025 Dec 31];Available from: \u3008https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=72e6b33c-0351\u20134070-9172-eeaa186c01d2#S12.3\u3009."},{"key":"10.1016\/j.jhlto.2026.100533_bib7","unstructured":"DailyMed - ENTECAVIR tablet, film coated [Internet]. [cited 2025 Dec 31];Available from: \u3008https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=73dea2a4-a596\u2013477f-b66d-5a80dd019837\u3009."},{"key":"10.1016\/j.jhlto.2026.100533_bib8","unstructured":"Universal Hepatitis B Vaccination in Adults Aged 19\u201359 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 - PubMed [Internet]. [cited 2025 July 3];Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/35358162\/\u3009."},{"issue":"9","key":"10.1016\/j.jhlto.2026.100533_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15464","article-title":"Hepatitis B vaccine compliance, serologic response, and durability in adult thoracic organ transplant recipients","volume":"38","author":"Chiu","year":"2024","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhlto.2026.100533_bib10","unstructured":"Chronic Hepatitis B | AASLD [Internet]. [cited 2025 July 3];Available from: \u3008https:\/\/www.aasld.org\/practice-guidelines\/chronic-hepatitis-b\u3009."},{"issue":"8","key":"10.1016\/j.jhlto.2026.100533_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1053-2498(01)00280-7","article-title":"Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area","volume":"20","author":"Ko","year":"2001","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SLA.0000000000005071","article-title":"Expanding the donor pool: first use of hepatitis B virus nat positive solid organ allografts into seronegative recipients","volume":"274","author":"Delman","year":"2021","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/TP.0000000000004759","article-title":"Use and outcomes of hepatitis B virus-positive grafts for kidney or heart transplantation in the United States From 1999 to 2021","volume":"108","author":"Singal","year":"2024","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/XCS.0000000000001288","article-title":"Friend or foe? safety and efficacy of hepatitis B viremic solid organ allograft into seronegative recipients","volume":"240","author":"Pratt","year":"2025","journal-title":"J Am Coll Surg"},{"issue":"7","key":"10.1016\/j.jhlto.2026.100533_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70236","article-title":"Hepatitis B virus NAT positive donors in non-hepatic organ transplant: quantifying viral loads to optimize recipient risk stratification and management in the prevention of donor-derived infection","volume":"39","author":"Tam","year":"2025","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.jhlto.2026.100533_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13514","article-title":"Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice","volume":"33","author":"Te","year":"2019","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.jhlto.2026.100533_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/TP.0b013e3181b4e1fd","article-title":"Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network For Organ Sharing Database","volume":"88","author":"Dhillon","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100533_bib18","unstructured":"Fong: Impact of hepatitis B core antibody status\u2026 - Google Scholar [Internet]. [cited 2025 Dec 29];Available from: https:\/\/scholar.google.com\/scholar_lookup?title=Impact%20of%20hepatitis%20B%20core%20antibody%20status%20on%20outcomes%20of%20cadaveric%20renal%20transplantation%3A%20Analysis%20of%20United%20network%20of%20organ%20sharing%20database%20between%201994%20and%201999&publication_year=2002&author=TL%20Fong&author=S%20Bunnapradist&author=SC%20Jordan&author=YW.%20Cho."},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","article-title":"Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature","volume":"14","author":"Mahboobi","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.tp.0000189930.89031.1b","article-title":"Kidney transplantation from Anti-HBc+ donors: results from a retrospective Italian study","volume":"81","author":"De Feo","year":"2006","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000165858.86067.a2","article-title":"Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation","volume":"80","author":"Hartwig","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0041-1345(01)02666-5","article-title":"Is there any risk of transmission of hepatitis B from heart donors hepatitis B core antibody positive?","volume":"34","author":"Blanes","year":"2002","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004196","article-title":"Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: a systematic review and meta-analysis","volume":"20","author":"Yin","year":"2023","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.jhlto.2026.100533_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhlto.2026.100533_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2023.100018","article-title":"Hepatitis B virus reactivation in hepatitis B core antibody positive lung transplant recipients","volume":"3","author":"Fernandez-Garcia","year":"2024","journal-title":"JHLT Open"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"10407","key":"10.1016\/j.jhlto.2026.100533_bib28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhlto.2026.100533_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.athoracsur.2022.11.002","article-title":"Outcomes of over 1000 heart transplants using hepatitis C-positive donors in the modern era","volume":"115","author":"Kwon","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15585\/mmwr.mm6803a2","article-title":"Characteristics of deceased solid organ donors and screening results for hepatitis B, C, and human immunodeficiency viruses - United States, 2010-2017","volume":"68","author":"Abara","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jtcvs.2022.08.019","article-title":"Trends in use and three-year outcomes of HCV-viremic donor lung transplants for HCV-seronegative recipients","volume":"165","author":"Ruck","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"10.1016\/j.jhlto.2026.100533_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1432-2277.2009.00926.x","article-title":"Transplantation in the patient with hepatitis C","volume":"22","author":"Dom\u00cdnguez-Gil","year":"2009","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1053-2498(03)00148-7","article-title":"Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation","volume":"23","author":"Haji","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2026.100533_bib34","unstructured":"HCV Guidance - Recommendations for Testing, Managing, and Treating Hepatitis C [Internet]. https:\/\/www.hcvguidelines.org\/. 2021 [cited 2025 Dec 23];Available from: \u3008https:\/\/www.hcvguidelines.org\/\u3009."},{"key":"10.1016\/j.jhlto.2026.100533_bib35","article-title":"Characteristics of deceased solid organ donors and screening results for hepatitis B, C, and human immunodeficiency viruses \u2014 United States, 2010\u20132017","volume":"68","author":"Abara MD","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep [Internet]"},{"key":"10.1016\/j.jhlto.2026.100533_bib36","unstructured":"HCV Guidance - Recommendations for Testing, Managing, and Treating Hepatitis C [Internet]. https:\/\/www.hcvguidelines.org\/. 2021 [cited 2025 Dec 30];Available from: \u3008https:\/\/www.hcvguidelines.org\/\u3009."},{"issue":"17","key":"10.1016\/j.jhlto.2026.100533_bib37","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.healun.2020.03.004","article-title":"Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement","volume":"39","author":"Aslam","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.jhlto.2026.100533_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies","volume":"37","author":"Schlendorf","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.healun.2022.01.010","article-title":"Clinical outcomes of heart transplantation using hepatitis c-viremic donors: a systematic review with meta-analysis","volume":"41","author":"Villegas-Galaviz","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.jhlto.2026.100533_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamacardio.2019.4748","article-title":"Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C","volume":"5","author":"Schlendorf","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001539","article-title":"Real-world experiences in the transplantation of hepatitis C-NAAT-positive organs","volume":"9","author":"Steinbrink","year":"2023","journal-title":"Transplant Direct"},{"issue":"12","key":"10.1016\/j.jhlto.2026.100533_bib43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.healun.2019.08.019","article-title":"Outcomes of heart transplantation from hepatitis C virus-positive donors","volume":"38","author":"Aslam","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15294","article-title":"Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors","volume":"38","author":"Kadosh","year":"2024","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.athoracsur.2022.05.072","article-title":"Donor and recipient hepatitis C status does not affect rejection in thoracic transplantation","volume":"115","author":"Ganapathi","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"10.1016\/j.jhlto.2026.100533_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13989","article-title":"Outcomes of the treatment with Glecaprevir\/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors","volume":"34","author":"Reyentovich","year":"2020","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.healun.2019.08.010","article-title":"The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate","volume":"38","author":"Gernhofer","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2023.09.015","article-title":"Early assessment of cardiac allograft vasculopathy risk among recipients of hepatitis C virus-infected donors in the current era","volume":"30","author":"Amancherla","year":"2024","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.jhlto.2026.100533_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14749","article-title":"One-year immunologic outcomes of lung transplantation utilizing hepatitis C-viremic donors","volume":"36","author":"Lewis","year":"2022","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib50","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1164\/rccm.201712-2614LE","article-title":"Lung transplantation from hepatitis C viremic donors to uninfected recipients","volume":"197","author":"Abdelbasit","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/acs.2020.01.03","article-title":"The impact of hepatitis C viremic donor lung allograft characteristics on post-transplantation outcomes","volume":"9","author":"Woolley","year":"2020","journal-title":"Ann Cardiothorac Surg"},{"issue":"2","key":"10.1016\/j.jhlto.2026.100533_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15260","article-title":"Using HCV-viremic organs for lung transplantation does not confer higher rejection rates compared to HCV-negative organs","volume":"38","author":"Afshar","year":"2024","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15325","article-title":"Hepatitis C viremic lung transplantation to aviremic recipients: comprehensive outcomes and post-transplant viremia","volume":"38","author":"Khan","year":"2024","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac550","article-title":"A pilot trial for prevention of hepatitis C virus transmission from donor to organ transplant recipient with short-course Glecaprevir\/Pibrentasvir","volume":"9","author":"Ramirez-Sanchez","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.jhlto.2026.100533_bib55","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.7326\/M23-2682","article-title":"Two-week direct-acting antiviral prophylaxis for kidney transplantation from donors with hepatitis C viremia to recipients without hepatitis C viremia: a small uncontrolled trial","volume":"176","author":"Desai","year":"2023","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jhlto.2026.100533_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib58","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1111\/ajt.16747","article-title":"Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants","volume":"21","author":"Gupta","year":"2021","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib59","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41467-018-08261-z","article-title":"Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion","volume":"10","author":"Galasso","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jhlto.2026.100533_bib60","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.healun.2018.06.012","article-title":"Cardiac transplantation from non-viremic hepatitis C donors","volume":"37","author":"Patel","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13476","article-title":"Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation","volume":"33","author":"Watson","year":"2019","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.healun.2020.03.004","article-title":"Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement","volume":"39","author":"Aslam","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.jhlto.2026.100533_bib63","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"The era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhlto.2026.100533_bib64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3748\/wjg.v24.i3.315","article-title":"Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates","volume":"24","author":"Gadiparthi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhlto.2026.100533_bib65","unstructured":"Hepatitis E [Internet]. [cited 2025 July 7]; Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-e\u3009."},{"issue":"13","key":"10.1016\/j.jhlto.2026.100533_bib66","first-page":"1237","article-title":"Hepatitis E","volume":"367","author":"Hoofnagle","year":"2012","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"7","key":"10.1016\/j.jhlto.2026.100533_bib67","first-page":"1935","article-title":"How should hepatitis E virus infection be defined in organ-transplant recipients?","volume":"13","author":"Kamar","year":"2013","journal-title":"Am\u00a0J\u00a0Transplant"},{"issue":"12","key":"10.1016\/j.jhlto.2026.100533_bib68","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3748\/wjg.v27.i12.1240","article-title":"Hepatitis E in solid organ transplant recipients: a systematic review and meta-analysis","volume":"27","author":"Hansrivijit","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jhlto.2026.100533_bib69","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.gastrohep.2023.01.010","article-title":"mTOR inhibitors a potential predisposing factor for chronic hepatitis E: results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)","volume":"46","author":"Riveiro-Barciela","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhlto.2026.100533_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw006","article-title":"Hepatitis E virus infection among solid organ transplant recipients at a North American Transplant Center","volume":"3","author":"Sue","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jhlto.2026.100533_bib71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib72","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"issue":"37","key":"10.1016\/j.jhlto.2026.100533_bib73","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","article-title":"Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment","volume":"26","author":"Aslan","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhlto.2026.100533_bib74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14787210.2023.2166932","article-title":"Diagnostic and management strategies for chronic hepatitis E infection","volume":"21","author":"Abravanel","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib75","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/ciz953","article-title":"Ribavirin for hepatitis E virus infection after organ transplantation: a large European Retrospective Multicenter Study","volume":"71","author":"Kamar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100533_bib76","unstructured":"Ribavirin: Package Insert \/ Prescribing Information \/ MOA [Internet]. Drugs.com. [cited 2025 Dec 30];Available from: \u3008https:\/\/www.drugs.com\/pro\/ribavirin.html\u3009."},{"issue":"9744","key":"10.1016\/j.jhlto.2026.100533_bib77","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"The Lancet"},{"issue":"10429","key":"10.1016\/j.jhlto.2026.100533_bib78","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Huang","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.jhlto.2026.100533_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11673","article-title":"Impact of hepatitis E virus screening in the UK Deceased Organ Donor Population","volume":"36","author":"Ushiro-Lumb","year":"2023","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib80","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/v17040502","article-title":"The prevalence, risk factors, and outcomes of hepatitis E virus infection in solid organ transplant recipients in a highly endemic area of Italy","volume":"17","author":"Binda","year":"2025","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.jhlto.2026.100533_bib81","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2008.165571","article-title":"Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation","volume":"58","author":"le Coutre","year":"2009","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhlto.2026.100533_bib82","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/v17040502","article-title":"The prevalence, risk factors, and outcomes of hepatitis E virus infection in solid organ transplant recipients in a highly endemic area of Italy","volume":"17","author":"Binda","year":"2025","journal-title":"Viruses"}],"container-title":["JHLT Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133426000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133426000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:38:16Z","timestamp":1779284296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950133426000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":82,"alternative-id":["S2950133426000546"],"URL":"https:\/\/doi.org\/10.1016\/j.jhlto.2026.100533","relation":{},"ISSN":["2950-1334"],"issn-type":[{"value":"2950-1334","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B, C, and E viruses in solid organ transplantation: donor and recipient perspectives","name":"articletitle","label":"Article Title"},{"value":"JHLT Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhlto.2026.100533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}],"article-number":"100533"}}